Switch View
© BusinessWire
05.11.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US40412C1018
HCA Healthcare Inc
HCA
LISTED
NYSE
HCA Healthcare Announces $1.5 Million HCA Healthcare Foundation Grant to Support March of Dimes' Low Dose, Big Benefits™ Campaign
News Preview
HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced the HCA Healthcare Foundation, through its Healthier Tomorrow Fund, will strengthen its collaboration with March of Dimes, a leading nonprofit fighting for the health of all moms and babies, through a new $1.5 million grant to support their Low Dose,...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US69404D1081
Pacific Biosciences of California Inc
PACB
LISTED
NASDAQ
HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes
News Preview
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by shor...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
05.11.2025
ISIN: US5898891040
Merit Medical Systems Inc
MMSI
LISTED
NASDAQ
Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
News Preview
SOUTH JORDAN, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced positive findings from the randomized AVF arm of the WAVE trial. These findings were presented during the Late-Breaking Clinical Trials session on Tuesday, November 4, 2025, at the Vascular In...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
05.11.2025
ISIN: VGG312491084
Establishment Labs Holdings Inc
ESTA
LISTED
NASDAQ
Establishment Labs Reports Third Quarter 2025 Financial Results
News Preview
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2025.
Third Quarter Highlights and Outlook (Unaudited)
Third quarter worldwide r...
Themefolio
Profiler
Peergroup
© Newsfile
05.11.2025
ISIN: CA14161Y2006
Cardiol Therapeutics Inc
CRDL
LISTED
TSX
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
News Preview
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: CA45074T1021
Ianthus Capital Holdings Inc.
IAN
LISTED
CSE
iAnthus Continues Expansion in Florida with GrowHealthy Dispensary Opening in Fort Myers
News Preview
iAnthus Continues Expansion in Florida with GrowHealthy Dispensary Opening in Fort Myers...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US59503A2042
Microbot Medical Inc.
MBOT
LISTED
NASDAQ
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
News Preview
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S....
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US45780L1044
Inogen Inc
INGN
LISTED
NASDAQ
Inogen Announces Third Quarter 2025 Financial Results
News Preview
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2025.
Recent Highlights
$92.4 million revenue, a year-over-year increase of 4.0%, marking the seventh consecutive quarter of mid-single-digit pe...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US1404752032
Sonida Senior Living Inc
SNDA
LISTED
NYSE
Sonida Senior Living Announces Strategic Merger with CNL Healthcare Properties, Inc. in a Stock and Cash Transaction Valued at Approximately $1.8 Billion, Creating $3 Billion Pure-Play Senior Housing Owner-Operator
News Preview
Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in senior living communities, and CNL Healthcare Properties, Inc. (“CHP”), a public non-traded real estate investment trust (“REIT”) which owns a national portfolio of high-quality senior housing communities, today announced a definitive mer...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US57777K1060
MaxCyte Inc
MXCT
LISTED
NASDAQ
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
News Preview
MaxCyte will now host its earnings conference call on November 12, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US92790C1045
Viridian Therapeutics Inc
VRDN
LISTED
NASDAQ
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
News Preview
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2025.
“The Viridian team continues to deliver stron...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
05.11.2025
ISIN: CA60255C8850
Mind Medicine (MindMed) Inc
MNMD
LISTED
NASDAQ
MindMed to Participate in Upcoming Investor Conferences
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:
Stifel 2025 Healthcare Conference
Fo...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US1598641074
Charles River Laboratories International Inc
CRL
LISTED
NYSE
Charles River Laboratories Provides Update on Strategic Review
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an update on its Board of Directors’ comprehensive strategic review of the Company’s business and growth prospects. The Board strongly supports the Company’s strategic direction and believes it should continue to focus on strengthening its leading scientific portfolio withi...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US56400P2011
MannKind Corporation
MNKD
LISTED
NASDAQ
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
MANNKIND CORPORATION REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US52635N1037
LENZ Therapeutics Inc
LENZ
LISTED
NASDAQ
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
News Preview
VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US74006W1080
Praxis Precision Medicines Inc
PRAX
LISTED
NASDAQ
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
News Preview
Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA scheduled for Q4 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: NL00150012L7
NewAmsterdam Pharma Company N.V.
NAMS
LISTED
NASDAQ
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
News Preview
– Marketing Authorization Applications for obicetrapib and FDC of obicetrapib plus ezetimibe accepted for review by European Medicines Agency –...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US4834971032
Kalvista Pharmaceuticals Inc
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences:
Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 8:40 a.m. EST
Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 1:...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US1598641074
Charles River Laboratories International Inc
CRL
LISTED
NYSE
Charles River Laboratories Announces Third-Quarter 2025 Results
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2025. For the quarter, revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion in the third quarter of 2024.
The impact of foreign currency translation increased reported revenue by 1.3%, and the divestiture of a small Safety As...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US3741631036
Geron Corp
GERN
LISTED
NASDAQ
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights.
"The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US52886X1072
Lexeo Therapeutics Inc
LXEO
LISTED
NASDAQ
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
News Preview
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US57055L1070
Marker Therapeutics, Inc.
MRKR
LISTED
NASDAQ
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
News Preview
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US76200L3096
Rezolute, Inc.
RZLT
LISTED
NASDAQ
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
News Preview
Webcast scheduled for Monday, November 10 at 12:00 pm EST Webcast scheduled for Monday, November 10 at 12:00 pm EST...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: KYG2545C1042
Crescent Biopharma, Inc.
CBIO
LISTED
NASDAQ
Crescent Biopharma to Present at November Investor Conferences
News Preview
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
Altimmune to Participate in Two Upcoming Investor Conferences
News Preview
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the follo...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US20454B1044
Compass Therapeutics Inc.
CMPX
LISTED
NASDAQ
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported third quarter 2025 financial results and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: IL0011316309
Mediwound Ltd
MDWD
LISTED
NASDAQ
MediWound to Report Third Quarter 2025 Financial Results
News Preview
MediWound to Report Third Quarter 2025 Financial Results...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US03073E1055
Cencora Inc
COR
LISTED
NYSE
Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results
News Preview
Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for t...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: CA22587M1068
Cresco Labs Inc
CL
LISTED
CSE
Cresco Labs Delivers Strong Q3, Maintains Market Leadership, and Unlocks New Growth Opportunities
News Preview
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the third quarter ended September 30, 2025. All financial inform...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US92337R1014
Vera Therapeutics Inc
VERA
LISTED
NASDAQ
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
Vera Therapeutics today reported its business highlights and financial results for the third quarter ended September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
News Preview
ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at an offering pr...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
News Preview
During 12-week post-treatment period, nimacimab plus semaglutide blunts weight regain compared to semaglutide alone in subset analysis During 12-week post-treatment period, nimacimab plus semaglutide blunts weight regain compared to semaglutide alone in subset analysis...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US0352551081
Anika Therapeutics Inc
ANIK
LISTED
NASDAQ
Anika Reports Third Quarter 2025 Financial Results
News Preview
Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US15102K1007
Celcuity Inc
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, November 12, 2025. Management will host a webcast/t...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US47973J1025
Joint Corp
JYNT
LISTED
NASDAQ
The Joint Corp. Board of Directors Authorizes an Additional $12 Million for Stock Repurchase Program
News Preview
SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, announced that its board of directors has authorized an additional $12 million for its stock repurchase program....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US09058V1035
BioCryst Pharmaceuticals Inc
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock. The RSUs were granted as o...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US04335A1051
Arvinas, Inc.
ARVN
LISTED
NASDAQ
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease –...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: GB00BMVP7Y09
Royalty Pharma PLC
RPRX
LISTED
NASDAQ
Royalty Pharma Reports Third Quarter 2025 Results
News Preview
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US10170A1007
Boundless Bio, Inc.
BOLD
LISTED
NASDAQ
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
News Preview
Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US3441741077
Foghorn Therapeutics Inc
FHTX
LISTED
NASDAQ
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
News Preview
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population ...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US5171251003
Larimar Therapeutics Inc
LRMR
LISTED
NASDAQ
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
News Preview
BALA CYNWYD, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2025 operating and financial results....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US8294011080
Sionna Therapeutics Inc
SION
LISTED
NASDAQ
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
News Preview
Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US91678A1079
Upstream Bio, Inc.
UPB
LISTED
NASDAQ
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
News Preview
– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12 weeks –...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
News Preview
ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the third quarter of 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US30233G2093
EyePoint Pharmaceuticals Inc
EYPT
LISTED
NASDAQ
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
News Preview
– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: IL0006290147
Teva Pharmaceutical Industries Ltd
TEVA
LISTED
TLV
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
News Preview
For an accessible version of this Press Release, please visit www.tevapharm.com...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US04683R1068
Atea Pharmaceuticals Inc
AVIR
LISTED
NASDAQ
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
News Preview
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 12,...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US03753U1060
Apellis Pharmaceuticals Inc
APLS
LISTED
NASDAQ
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
News Preview
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US35168W1036
Fractyl Health Inc
GUTS
LISTED
NASDAQ
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
News Preview
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on W...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US4448591028
Humana Inc
HUM
LISTED
NYSE
Humana Reports Third Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted EPS Guidance
News Preview
Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended September 30, 2025 (3Q25) versus the quarter ended September 30, 2024 (3Q24) and for the nine months ended September 30, 2025 (YTD 2025) versus the nine months ended September 30, 2024 (YTD 2024) as noted in the tables belo...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: GB00BYMT0J19
LivaNova PLC
LIVN
LISTED
NASDAQ
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance.
Financial Summary and Highlights(1)
Third-quarter revenue of $357.8 million increased 12.5% on a reported basis, 11.0% on a constant-currency basis, and 12.5% on an o...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US75629V1044
Recursion Pharmaceuticals Inc
RXRX
LISTED
NASDAQ
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US67577C1053
Ocugen Inc
OCGN
LISTED
NASDAQ
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
News Preview
Conference Call and Webcast Today at 8:30 a.m. ET Conference Call and Webcast Today at 8:30 a.m. ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US34965KAA51
Fortrea Holdings, Inc.
FTRE
LISTED
NASDAQ
Fortrea Reports Third Quarter 2025 Results
News Preview
For the three months ended September 30, 2025, from continuing operations:...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US75629V1044
Recursion Pharmaceuticals Inc
RXRX
LISTED
NASDAQ
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
News Preview
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US7504911022
RadNet Inc
RDNT
LISTED
NASDAQ
RadNet Expands Comprehensive Remote Scanning Offering with Acquisition of Alpha RT’s Assets
News Preview
DeepHealth commercializes remote-imaging offering featuring TechLive™ remote scanning and Alpha RT’s MRI staffing services, training and safety software....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: AU000000IMC7
Immuron Limited
IMC
LISTED
ASX
Immuron IMM-529 IND approved by FDA
News Preview
Key Points...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
News Preview
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Telix to Participate in UBS and Jefferies Global Healthcare Conferences
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL (U.S.) and in the Jefferies Global Healthcare Conference in London (UK)....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
